These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 20943046

  • 1. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
    Antiga E, Volpi W, Chiarini C, Cardilicchia E, Filì L, Manuelli C, Parrochi P, Fabbri P, Caproni M.
    Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
    Lee JH, Youn JI, Kim TY, Choi JH, Park CJ, Choe YB, Song HJ, Kim NI, Kim KJ, Lee JH, Yoo HJ.
    BMC Dermatol; 2016 Jul 25; 16(1):11. PubMed ID: 27455955
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
    Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P.
    J Clin Immunol; 2009 Mar 25; 29(2):210-4. PubMed ID: 18763027
    [Abstract] [Full Text] [Related]

  • 5. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P, Del Giglio M, Cotena C, Girolomoni G.
    Br J Dermatol; 2008 Jun 25; 158(6):1345-9. PubMed ID: 18410408
    [Abstract] [Full Text] [Related]

  • 6. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.
    de Groot M, Teunissen MB, Picavet DI, de Rie MA, Bos JD.
    Exp Dermatol; 2010 Aug 25; 19(8):754-6. PubMed ID: 20482616
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
    Mahiques L, Pitarch G, Sánchez-Carazo JL, Pérez-Ferriols A, Soriano CJ, Alegre V.
    Actas Dermosifiliogr; 2007 Oct 25; 98(8):539-44. PubMed ID: 17919428
    [Abstract] [Full Text] [Related]

  • 14. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 25; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 15. Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease.
    Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M.
    J Leukoc Biol; 2013 Dec 25; 94(6):1337-43. PubMed ID: 23990625
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO, Kıran R, Salman S, Cağlayan C, Aktürk AS, Bayramgurler D, Bilen N.
    J Drugs Dermatol; 2013 Sep 25; 12(9):1039-43. PubMed ID: 24002153
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar 25; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 19. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
    van Lingen RG, Körver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM.
    Br J Dermatol; 2008 Jul 25; 159(1):91-6. PubMed ID: 18476954
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.